COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,617 Articles (22,913 medRxiv, 8,704 bioRxiv)

Most recent first Previous |  Page 1849: Articles 18481-18490  | Next

SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020
Chisolm, T., Walker, J. P., Leys, Y., Butterfield, T. R., Medley, C., Thompson, T. K., Reynolds-Campbell, G., Mulder, W. H., Campbell Mitchell, M., Anzinger, J. J.
10.1101/2021.02.08.21251367 — Posted: 2021-02-11
Association of state social distancing restrictions with nursing home COVID-19 and non-COVID-19 outcomes
Li, Y., Cheng, Z., Cai, X., Mao, Y., Temkin-Greener, H.
10.1101/2021.02.08.21251382 — Posted: 2021-02-11
Estimating real-world COVID-19 vaccine effectiveness in Israel
Aran, D.
10.1101/2021.02.05.21251139 — Posted: 2021-02-11 Discussion: Onsite
Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients
Das, S., Pearson, M., Taylor, K., Bouchet, V., Moller, G. L., Hall, T. O., Strivens, M., Tzeng, K. T. H., Gardner, S.
10.1101/2021.02.08.21250899 — Posted: 2021-02-11
How much do superspreaders matter? Epidemic dynamics in inhomogeneous populations
Kawagoe, K., Rychnovsky, M., Chang, S. Y., Huber, G., Li, L. M., Miller, J., Pnini, R., Veytsman, B., Yllanes, D.
10.1101/2021.02.08.21251386 — Posted: 2021-02-11
Country specific mutational profile of SARS-CoV-2 in pre- and post-international travel ban: Effect on vaccine efficacy
Laha, S., Chatterjee, R.
10.1101/2021.02.08.21251359 — Posted: 2021-02-11
Before the Surge: Molecular Evidence of SARS-CoV-2 in New York City Prior to the First Report
Hernandez, M. M., Gonzalez-Reiche, A. S., Alshammary, H., Fabre, S., Khan, Z., van De Guchte, A., Obla, A., Ellis, E., Sullivan, M. J., Tan, J., Alburquerque, B., Soto, J., Wang, C.-Y., Sridhar, S. H., Wang, Y.-C., Smith, M., Sebra, R., Paniz-Mondolfi, A. E., Gitman, M. R., Nowak, M. D., Cordon-Cardo, C., Luksza, M., Krammer, F., van Bakel, H., Simon, V., Sordillo, E. M.
10.1101/2021.02.08.21251303 — Posted: 2021-02-11
A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemic
Lule Bugembe, D., Phan, M. V. T., Ssewanyana, I., Semanda, P., Nansumba, H., Dhaala, B., Nabadda, S., O'Toole, A., Rambaut, A., Kaleebu, P., Cotten, M.
10.1101/2021.02.08.21251393 — Posted: 2021-02-11
Clinical Validation of Automated and Rapid mariPOC SARS-CoV-2 Antigen Test
Koskinen, J. M., Antikainen, P., Hotakainen, K., Haveri, A., Ikonen, N., Savolainen-Kopra, C., Koskinen, J. O.
10.1101/2021.02.08.21250086 — Posted: 2021-02-11
Accelerating COVID-19 research with graph mining and transformer-based learning
Tyagin, I., Kulshrestha, A., Sybrandt, J., Matta, K., Shtutman, M., Safro, I.
10.1101/2021.02.11.430789 — Posted: 2021-02-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).